Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | PPARG | P37231 | 12/20 | 0.51 |
| ▸ | MPC2 | O95563 | 2/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1299773 | 0.88 | HPGD (0.62) | MAPTCYP3A4MEN1ALDH1A1TP53 | |
| SCHEMBL1300284 | 0.87 | HPGD (0.64) | MAPTCYP3A4MEN1ALDH1A1TP53 | |
| SCHEMBL8310671 | 0.86 | FFAR1 (0.63) | MAPTCYP3A4MEN1ALDH1A1TP53 | |
| SCHEMBL8310673 | 0.86 | FFAR1 (0.63) | MAPTCYP3A4MEN1ALDH1A1TP53 | |
| SCHEMBL11033260 | 0.81 | HPGD (0.58) | MAPTCYP3A4MEN1ALDH1A1TP53 | |
| SCHEMBL3399407 | 0.81 | MAPT (0.62) | MAPTCYP3A4MEN1ALDH1A1TP53 | |
| SCHEMBL1299561 | 0.80 | HRH3 (0.63) | MAPTCYP3A4MEN1ALDH1A1TP53 | |
| SCHEMBL1300308 | 0.79 | HRH3 (0.65) | MAPTCYP3A4MEN1ALDH1A1TP53 | |
| SCHEMBL17536165 | 0.78 | FFAR1 (0.69) | MAPTCYP3A4MEN1ALDH1A1TP53 | |
| SCHEMBL16474084 | 0.78 | HPGD (0.49) | MAPTCYP3A4MEN1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682125-B2 | Compositions and methods for treating cognitive deficits | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-06-20 | — | — | US | claimed |
| US-6579893-B1 | Related thiazolidinediones | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-06-17 | — | — | US | claimed |
| US-9682125-B2 | Compositions and methods for treating cognitive deficits | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150374792-A1 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DEFICITS | CASE WESTERN RESERVE UNIVERSITY | 2015-12-31 | — | — | US | disclosed |
| US-9132170-B2 | Compositions and methods for treating cognitive deficits | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | UNIV CASE WESTERN RESERVE (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2766018-A2 | RXR AGONISTS COMPOUNDS AND METHODS | Case Western Reserve University (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20130190230-A1 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DEFICITS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2013056232-A2 | RXR AGONISTS COMPOUNDS AND METHODS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-04-18 | — | — | WO | disclosed |
| EP-2451455-A2 | RXR AGONIST COMPOUNDS AND METHODS | Case Western Reserve University (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120115912-A1 | RXR AGONIST COMPOUNDS AND METHODS | LANDRETH GARY E (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2011006157-A2 | RXR AGONIST COMPOUNDS AND METHODS | CASE WESTERN RESERVE UNIVERSITY (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374792-A1 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DEFICITS | IAPP, APP, PYGB | MAPT 18/4885CYP3A4 4766/4885MEN1 802/4885 |
| US-20130190230-A1 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DEFICITS | IAPP, APP, PYGB | MAPT 18/4885CYP3A4 4766/4885MEN1 802/4885 |
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | RXRA, RXRB, RXRG | MAPT 1395/4885CYP3A4 1058/4885MEN1 4760/4885 |
| US-20120115912-A1 | RXR AGONIST COMPOUNDS AND METHODS | RXRA, RXRB, RXRG | MAPT 3596/4885CYP3A4 568/4885MEN1 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.